Performance Forecasts - Yinglian Co., Ltd. expects a net profit growth of 1531.13% to 1672.97% year-on-year for the first three quarters [1] - Dalian Heavy Industry anticipates a net profit growth of 19.91% to 28.52% year-on-year for the first three quarters [1] Project Investments - Wharton Technology plans to invest in the enhancement of membrane materials and membrane components [1] - Jiufeng Energy intends to invest in a coal-to-natural gas project in Xinjiang [1] Contract Awards - Qiaoyin Co., Ltd. is pre-awarded a contract worth approximately 512 million yuan for integrated sanitation operations in Laishui County, Baoding City, Hebei Province [1] - Dash Smart signed a contract for a smart hospital project worth 113 million yuan [1] Equity Acquisitions - Conch New Materials plans to acquire 51% equity in North China Plastics [1] - Suochen Technology intends to acquire 60% equity in Likong Technology [1] - Jingye Intelligent plans to acquire 51% equity in Hefei Shengwen for 108 million yuan [1] - Landi Group plans to acquire 20.1667% equity in Jujia Technology for 121 million yuan [1] Share Buybacks - Hanshuo Technology plans to repurchase shares worth between 150 million yuan and 300 million yuan [2] - Youke De intends to spend between 8 million yuan and 10 million yuan on share buybacks [2] H-Shares - Jinghe Integrated Circuit has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [2] - Lingyi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - Changchun High-tech has submitted an application for the issuance of H-shares [2] Shareholding Changes - Senba Sensor's actual controller plans to reduce holdings by no more than 1.09% [3] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [3] - Andeli's BVI Donghua plans to reduce holdings by no more than 1.00% [3] - Zhiyang Innovation's controlling shareholder and its concerted actioner plan to reduce a total of no more than 4.225 million shares [3] - Xizi Clean Energy's chairman plans to increase holdings by 30 million to 50 million yuan [3] Other Activities - Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development projects [3] - Huaxin Xinchang has received project designation notification from Jiangqi Group [3] - Jinpu Garden plans to raise no more than 129 million yuan through a private placement to Nanjing Lisen [3]

36氪获悉，长春高新公告，公司已于2025年9月29日向香港联合交易所有限公司（以下简称"香港联交 所"）递交了发行境外上市外资股（H股）股票并在香港联交所主板上市（以下简称"本次发行上市"） 的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。本次发行上市事项的相关申请资 料为公司按照香港证券及期货事务监察委员会及香港联交所的要求编制和刊发，为草拟版本，其所载资 料可能会适时作出更新及修订，投资者不应根据其中的资料作出任何投资决定。 ...

Core Viewpoint - Changchun High-tech has officially submitted its main board listing application in Hong Kong, marking a significant step in its internationalization strategy [1] Group 1: Company Strategy and Financials - The company aims to accelerate its global strategy and expand financing channels to support high-intensity R&D and pipeline expansion [1] - In the first half of this year, R&D investment increased by 17.32% year-on-year, reaching 1.335 billion yuan, with R&D expenditure accounting for 20.21% of revenue [1] - Changchun High-tech has established a strong and diverse product portfolio in various therapeutic areas, including endocrine and metabolic diseases, women's health, immune and respiratory diseases, oncology, vaccines, and traditional Chinese medicine [1] Group 2: Business Development and Partnerships - The company has transitioned from a "self-research single-wheel drive" model to a "self-research + business development dual-wheel drive" strategy, particularly evident in its subsidiary, Changchun Jinsai Pharmaceutical [2] - In September, Changchun Jinsai announced a collaboration with ALK-Abelló A/S to co-develop and commercialize allergy immunotherapy products in China, gaining exclusive rights to three ALK products [2] - The long-term goal for Changchun Jinsai is to become a leading player in the respiratory field in China, expanding its business footprint and industry influence [2] Group 3: Market Context and Future Outlook - Since the implementation of the 18A listing rules in 2018, Hong Kong has become a preferred listing destination for biotech companies, supported by recent policy enhancements [3] - The Hong Kong market offers policy inclusivity and an international ecosystem, facilitating overseas business funding and foreign exchange settlement [3] - The company plans to enhance its clinical pipeline through sustained high R&D investment and expand its global market presence via partnerships and product diversification [3]

Group 1 - The core viewpoint of the article highlights the strong demand in the energy storage and solid-state battery sectors, driven by unexpected increases in lithium iron phosphate (LiFePO4) production, which is expected to boost upstream lithium salt and phosphoric chemical industries [1][10]. - According to Dongwu Securities, the shortage of energy storage cells is expected to persist until the second half of 2026, with low-priced orders seeing a price increase of 1-3 cents per watt-hour, leading to significant improvements in manufacturer profitability [2]. - The production capacity of various companies is projected to increase significantly, with notable expansions planned for companies like Hunan YN and Fulin Precision, indicating a robust growth trajectory in the energy storage market [3]. Group 2 - The A-share market experienced a collective rise, with major indices showing significant gains, particularly in the financial sector, which saw a surge in trading volume and investor confidence [10][29]. - The energy storage sector is rebounding strongly, with leading battery manufacturers reporting full production capacity and some orders extending into early next year, reflecting the ongoing demand [11]. - The satellite communication sector is also gaining traction, with major telecom companies receiving licenses to operate satellite mobile communication services, enhancing communication capabilities in various applications [14].

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of Teborone tablets in China [2] Company Summary - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has successfully obtained a drug registration certificate for Teborone tablets [2]

Core Points - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for its application of αN02 injection of follicle-stimulating hormone, which has been approved for marketing in China [1] Company Summary - The approval of the αN02 injection marks a significant milestone for Changchun Jinsai Pharmaceutical, enhancing its product portfolio in the pharmaceutical market [1] - This development indicates the company's commitment to expanding its presence in the biopharmaceutical sector [1] Industry Summary - The approval of new drugs like αN02 injection reflects the ongoing growth and regulatory advancements within the pharmaceutical industry in China [1] - The successful registration of this drug may lead to increased competition and innovation in the reproductive health segment of the pharmaceutical market [1]

Group 1 - The core viewpoint of the news is that Changchun High-tech Industry (Group) Co., Ltd. has submitted a listing application, with CITIC Securities International as the sole sponsor [1] - Established in 1993, the company initially focused on infrastructure and real estate development in Changchun, and strategically shifted its focus to the pharmaceutical industry in 1996 [1] - Changchun High-tech has developed a comprehensive capability in research, manufacturing, and commercialization through investments in subsidiaries such as Jinsai Pharmaceutical, Baike Biological, and Huakang Pharmaceutical [1] Group 2 - The company has become a leading innovation-driven pharmaceutical group in China, covering therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine [1] - According to Frost & Sullivan, Changchun High-tech is one of the few pharmaceutical companies in China that has achieved full industry chain capabilities in the aforementioned drug types [1] - The product portfolio includes over 45 commercialized drugs, with more than 20 being first-in-class products globally and/or in China [1] Group 3 - Recently, the company has faced short-term pressure, with over 90% of its drug sales revenue coming from six major products [2] - A projected revenue decline of 7.5% year-on-year for 2024 is attributed to the normalization of shingles vaccine sales and a decrease in sales of the company's water injection product [2] - Financial data shows that the company achieved revenues of 12.63 billion, 14.57 billion, 13.47 billion, and 6.60 billion RMB for the years 2022, 2023, 2024, and the first half of 2025, respectively, with significant profit declines [2]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Drug Registration Certificate approved by the National Medical Products Administration, allowing the launch of Tibralon Tablets in the domestic market [1] Company Summary - Jinsai Pharmaceutical has developed Tibralon Tablets, which are classified as a selective estrogen receptor modulator, specifically designed to treat low estrogen symptoms caused by natural or surgical menopause in women [1] - Tibralon Tablets are categorized as a Class 4 oral chemical drug [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of its drug, FSH-CTP injection, in China [1] Group 1: Company Information - The approved product is a long-acting recombinant human follicle-stimulating hormone (FSH-CTP) injection, developed using genetic engineering technology [1] - FSH-CTP is designed to replace the traditional 7-day regimen of follicle-stimulating hormone injections with a single subcutaneous injection [1] - The product falls under the category of therapeutic biological products, classified as type 3.2 [1] Group 2: Industry Context - The approval of FSH-CTP injection represents a significant advancement in reproductive health treatments, potentially improving patient compliance and treatment outcomes [1] - The use of CHO cell expression technology for drug development highlights the ongoing innovation within the biopharmaceutical industry in China [1]

Group 1 - The core point of the article is that Changchun High-tech (000661) announced the approval of two drugs by the National Medical Products Administration for market launch in China [1] Group 2 - Changchun High-tech's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the drug registration certificate for Tebentafusp tablets, which has been approved for sale in the domestic market [1] - The company also announced that its subsidiary received the drug registration certificate for Follitropin αN02 injection, which has also been approved for sale in the domestic market [1]